The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...

The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

The AIntibody Challenge seeks to rigorously test AI-driven antibody design and in silico predictions against experimentally validated datasets. Focusing on antibodies targeting the RBD ...

While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...

The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s ...

The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...